Ionis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Noncontrolling Interest
Ionis Pharmaceuticals, Inc. (IONS) reported Net Income (Loss) Attributable to Noncontrolling Interest of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2023-02-22
- Ionis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2021-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2021-09-30 was $0.00.
- Ionis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2021-06-30 was $0.00.
- Ionis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for the quarter ending 2021-03-31 was $0.00.
- Ionis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2022 was $0.00.
- Ionis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2021 was $0.00.
- Ionis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2020 was -$35.48M, a 489.21% decline from fiscal 2019.
- Ionis Pharmaceuticals, Inc. net income (loss) attributable to noncontrolling interest for fiscal 2019 was $9.12M.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss) Attributable to Noncontrolling Interest 12 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-22 | ||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $0.00 derived: sum of 3 quarters · filed 2023-02-22 | $0.00 10-K · filed 2023-02-22 | |||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | -$1.16M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | -$1.16M derived: sum of 3 quarters · filed 2023-02-22 | -$13.30M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 | -$1.16M derived: sum of 2 quarters · filed 2023-02-22 | -$13.30M derived: sum of 3 quarters · filed 2023-02-22 | -$25.23M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2020-12-31 | -$1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$13.30M derived: sum of 2 quarters · filed 2023-02-22 | -$25.23M derived: sum of 3 quarters · filed 2023-02-22 | -$35.48M 10-K · filed 2023-02-22 | |||
| 2020-09-30 | -$12.15M 10-Q · filed 2021-11-03 | -$24.07M derived: sum of 2 quarters · filed 2021-11-03 | -$34.33M 10-Q · filed 2021-11-03 | -$14.78M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | -$11.92M 10-Q · filed 2021-08-04 | -$22.18M 10-Q · filed 2021-08-04 | -$2.64M derived: sum of 3 quarters · filed 2022-02-25 | -$10.37M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | -$10.25M 10-Q · filed 2021-05-05 | $9.29M derived: sum of 2 quarters · filed 2022-02-25 | $1.56M derived: sum of 3 quarters · filed 2022-02-25 | -$7.58M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | $19.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $11.81M derived: sum of 2 quarters · filed 2022-02-25 | $2.67M derived: sum of 3 quarters · filed 2022-02-25 | $9.12M 10-K · filed 2022-02-25 | |||
| 2019-09-30 | -$7.73M 10-Q · filed 2020-11-04 | -$7.73M 10-Q · filed 2019-11-06 | -$16.87M derived: sum of 2 quarters · filed 2020-11-04 | -$10.43M 10-Q · filed 2020-11-04 | -$27.77M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-06-30 | -$9.14M 10-Q · filed 2020-08-05 | -$2.69M 10-Q · filed 2020-08-05 | -$20.04M derived: sum of 3 quarters · filed 2021-02-24 | -$35.84M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2019-03-31 | $6.44M 10-Q · filed 2020-05-06 | -$10.90M derived: sum of 2 quarters · filed 2021-02-24 | -$26.71M derived: sum of 3 quarters · filed 2021-02-24 | -$42.92M derived: sum of 4 quarters · filed 2021-02-24 | |||
| 2018-12-31 | -$17.34M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$33.15M derived: sum of 2 quarters · filed 2021-02-24 | -$49.37M derived: sum of 3 quarters · filed 2021-02-24 | -$58.76M 10-K · filed 2021-02-24 | |||
| 2018-09-30 | -$15.81M 10-Q · filed 2019-11-06 | -$32.02M derived: sum of 2 quarters · filed 2019-11-06 | -$41.41M 10-Q · filed 2019-11-06 | -$47.66M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-06-30 | -$16.21M 10-Q · filed 2019-08-08 | -$25.61M 10-Q · filed 2019-08-08 | -$31.85M derived: sum of 3 quarters · filed 2020-03-02 | -$36.74M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2018-03-31 | -$9.39M 10-Q · filed 2019-05-09 | -$15.64M derived: sum of 2 quarters · filed 2020-03-02 | -$20.52M derived: sum of 3 quarters · filed 2020-03-02 | -$20.52M derived: sum of 4 quarters · filed 2020-03-02 | |||
| 2017-12-31 | -$6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$11.13M derived: sum of 2 quarters · filed 2020-03-02 | -$11.13M derived: sum of 3 quarters · filed 2020-03-02 | -$11.13M 10-K · filed 2020-03-02 | -$11.33M 10-K · filed 2018-02-28 | ||
| 2017-09-30 | -$4.88M 10-Q · filed 2018-11-06 | -$3.92M 10-Q · filed 2017-11-07 | -$4.88M derived: sum of 2 quarters · filed 2018-11-06 | -$4.88M 10-Q · filed 2018-11-06 | -$3.92M 10-Q · filed 2017-11-07 | -$4.88M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-07 | $0.00 10-Q · filed 2018-08-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-01 | $0.00 derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 derived: sum of 3 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | |||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 | ||||||
| 2009-12-31 | -$1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$2.62M derived: sum of 2 quarters · filed 2012-02-29 | -$3.48M derived: sum of 3 quarters · filed 2012-02-29 | -$4.39M 10-K · filed 2012-02-29 | |||
| 2009-09-30 | -$1.14M 10-Q · filed 2010-11-05 | -$1.99M derived: sum of 2 quarters · filed 2010-11-05 | -$2.91M 10-Q · filed 2010-11-05 | ||||
| 2009-06-30 | -$857.00K 10-Q · filed 2010-08-09 | -$1.77M 10-Q · filed 2010-08-09 | |||||
| 2008-12-31 | -$4.73M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |